-
Par Pharmaceutical, Inc. et al v. TWi PHARMACEUTICALS, INC. DC CAFC
- 1:11-cv-02466
- D. Md.
- Judge: Catherine C. Blake +1
- Filed: 09/01/2011
- Closed: 02/21/2014
- Latest Docket Entry: 02/08/2017
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
1
Accused
Product
1
Patent-in-Suit
905
Days in
Litigation
-
Par Pharmaceutical, Inc. et al v. TWi PHARMACEUTICALS, INC. DC CAFC
- 1:11-cv-02466
- D. Md.
- Judge: Catherine C. Blake +1
- Filed: 09/01/2011
- Closed: 02/21/2014
- Latest Docket Entry: 02/08/2017
- PACER
- Docket updated daily
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of increasing the body mass in a human patient suffering from anorexia, cachexia, or loss of body mass, comprising administering to the human patient a megestrol formulation, wherein: (a) the megestrol acetate formulation is a dose of about
view more
|
Invalid (103)
Entry 212 |
2 |
The method of claim 1, wherein the anorexia, cachexia or loss of body mass is associated with a diagnosis of HIV or AIDS in the human patient.
|
Invalid (103)
Entry 212 |
4 |
A method of increasing the body mass in a human patient suffering from anorexia, cachexia, or loss of body mass, comprising administering to the human patient a megestrol formulation, wherein: (a) the megestrol acetate formulation is a dose of about
view more
|
Invalid (103)
Entry 212 |
5 |
The method of claim 4, wherein the difference in C<sub>max </sub>is less than about 60%.
|
Invalid (103)
Entry 212 |
10 |
The method of claim 1, wherein the anorexia, cachexia or loss of body mass is associated with HIV or AIDS.
|
Invalid (103)
Entry 212 |
12 |
The method of claim 1, wherein a maximum blood plasma concentration of megestrol of at least about 700 ng/ml is obtained.
|
Invalid (103)
Entry 212 |
13 |
The method of claim 12, wherein the maximum blood plasma concentration of megestrol is at least about 700 ng/ml and is attained in less than 5 hours after administration of the megestrol formulation.
|
Invalid (103)
Entry 212 |
14 |
The method of claim 1, wherein the maximum blood plasma concentration of megestrol is at least about 400 ng/ml and is attained in less than 5 hours after administration of the megestrol formulation.
|
Invalid (103)
Entry 212 |
15 |
The method of claim 1, wherein a mean C<sub>max </sub>of about 300 ng/ml to about 2000 ng/ml is obtained after a single administration of the formulation in the human subject in a fasted state.
|
Invalid (103)
Entry 212 |
16 |
The method of claim 1, wherein the surface stabilizer is selected from the group consisting of nonionic, cationic, ionic, and zwitterionic surfactants.
|
Invalid (103)
Entry 212 |
17 |
The method of claim 1, wherein the surface stabilizer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin,
view more
|
Invalid (103)
Entry 212 |
19 |
The method of claim 4, wherein the formulation exhibits a mean C<sub>max </sub>selected from the group consisting of greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 30%, greater than
view more
|
Invalid (103)
Entry 212 |
21 |
The method of claim 4, wherein the anorexia, cachexia or loss of body mass is associated with a diagnosis of HIV or AIDS in the human patient.
|
Invalid (103)
Entry 212 |
24 |
The method of claim 4, wherein the anorexia, cachexia or loss of body mass is associated with HIV or AIDS.
|
Invalid (103)
Entry 212 |
All Claims |
NA
|
Valid
Entry 141 |
-
Infringement
Alkermes Pharma Ireland Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
US 7,101,576 B2 | All Asserted Claims |
No infringement
Entry 141
|
Par Pharmaceutical, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
US 7,101,576 B2 | All Asserted Claims |
No infringement
Entry 141
|